Clinical Treatment in Colorectal Cancer: Other Aspects
In this chapter we will discuss current concepts in the treatment of colorectal cancer (CRC)—surgery, chemotherapy, and radiotherapy. We will explain how to choose the adequate treatment approach and answer the following questions: When complete surgical removal is indicated, should chemotherapy be applied before, or instead after, the surgery? Is radiotherapy an option in colorectal cancer? We will widely discuss the surgical approaches in the CRC and currently available drugs (their medical indications, mechanism of action, spectrum of adverse effects). Moreover, we will delineate further perspectives in the CRC management—DNA sequencing, the role of small interfering RNA, and microRNA.
KeywordsColorectal cancer Colorectal cancer chemotherapy Colorectal cancer radiotherapy
Epidermal growth factor receptor
Food and Drug Administration
Double-action formula of 5-fluorouracil and oxaliplatin
Triple-action formula of 5-fluorouracil, leucovorin, and irinotecan
Triple-action formula of 5-fluorouracil, leucovorin, and oxaliplatin
Metastatic colorectal cancer
Vascular endothelial growth factor
The authors have no conflicts of interest to disclose.
Supported by grants from the Medical University of Lodz (502-03/1-156-04/502-14-297 to MZ), National Science Centre (#UMO-2013/11/N/NZ7/00724 and UMO-2014/12/T/NZ7/00252 to MZ), and Ministry of Science and Higher Education (Iuventus Plus 5 Program #IP2015 089474 to MZ). AJ and MZ are recipients of the Polish L’Oréal-UNESCO Awards for Women in Science. MZ is a recipient of Polpharma Scientific Foundation Scholarship.
- 2.National Comprehensive Cancer Network. Colon Cancer (version 2.2017) [Internet]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf [cited 20 Jul 2005].
- 3.FOxTROT Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 2012;13(11):1152–60. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1470204512703480 CrossRefPubMedPubMedCentralGoogle Scholar
- 13.National Cancer Institute at the National Institutes of Health. FDA Approval for Cetuximab. 2013. Available from: https://www.cancer.gov/about-cancer/treatment/drugs/fda-cetuximab
- 14.Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12. doi: 10.1016/S0140-6736(12)61900-X.CrossRefPubMedGoogle Scholar
- 16.National Cancer Institute at the National Institutes of Health. Trifluridine and Tipiracil Hydrochloride. 2015. Available from: https://www.cancer.gov/about-cancer/treatment/drugs/trifluridine-tipiracilhydrochloride
- 17.FDA approves new oral medication to treat patients with advanced colorectal cancer. 2015; Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm463650.htm
- 18.FDA Approval for Ziv-Aflibercept. 2013. Available from: https://www.cancer.gov/about-cancer/treatment/drugs/fda-ziv-aflibercept
- 22.Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene. 2009;28(10):1385–92. Available from: http://www.nature.com/doifinder/10.1038/onc.2008.474 CrossRefPubMedGoogle Scholar
- 25.Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22(10):1797–806. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15067028 CrossRefPubMedGoogle Scholar